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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: The present study was designed to investigate the potential of sodium
butyrate, a histone deacetylase (HDAC) inhibitor, in chronic constriction injury (CCI)-induced
neuropathic pain in rats.
Methods: Neuropathic pain was induced by placing four loose ligatures around the sciatic
nerve. Acetone drop, Von frey hair, pin prick and hot plate tests were performed to assess cold
allodynia, mechanical allodynia, and mechanical and heat hyperalgesia, respectively. The
level of tumor necrosis factor (TNF)-a was measured in the sciatic nerve as an inflammatory
marker.
Results: CCI was associated with the development of cold allodynia, mechanical allodynia, and
mechanical and heat hyperalgesia, along with an increase in TNF-a level. Administration of so-
dium butyrate (200 and 400 mg/kg, oral) for 14 days in CCI-subjected rats significantly atten-
uated behavior related to injury-induced pain and the increase in TNF-a level.
Conclusion: It may be concluded that the anti-inflammatory actions mediated by sodium buty-
rate are responsible for its beneficial effects in neuropathic pain in rats.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Neuropathic pain has been described as the “most terrible of
all tortures which a nerve wound may inflict” and arises as aof Pharmaceutical Sciences
ity, Patiala 147002, Punjab,
ahoo.co.in (A.S. Jaggi).
ight ª 2013, Elsevier Taiwan LLC
3.05.013consequence of nerve injury either of the peripheral or
central nervous system. Following peripheral nerve injury, a
cascade of events in the primary afferents leads to periph-
eral sensitization, resulting in spontaneous nociceptor ac-
tivity, decreased threshold, and increased response to
suprathreshold stimuli.1 Despite the recent advances in
identification of peripheral and central sensitization mech-
anisms related to nervous system injury, the effective
treatment of patients suffering from neuropathic pain re-
mains a clinical challenge. Although numerous treatment& Formosan Medical Association. All rights reserved.
922 A. Kukkar et al.options are available for relieving neuropathic pain, there is
no consensus on the most appropriate treatment.2 Conse-
quently, there is still a considerable need to explore novel
treatment modalities for neuropathic pain management.
HDACs (also called lysine deacetylases) are a class of en-
zymes that regulate the gene expression by removing the
acetyl group from ε-N-acetyl lysine amino acid present on
histone proteins.3,4 Several studies have suggested the upre-
gulation ofHDAC indifferent inflammatorydiseases, including
polycythemia vera, essential thrombocythemia, rheumatoid
arthritis, neuroblastoma, and pancreatic cancer.5e7 Accord-
ingly, HDAC inhibitors are proposed to have significant thera-
peutic potential as anti-inflammatoryand immunosuppressive
drugs.8 Preclinical studies have shown that HDAC inhibitors
produce beneficial effects in various pathological conditions
such as rheumatoid arthritis,9 RubinsteineTaybi syndrome,
Rett syndrome, Friedreich’s ataxia, Huntington’s disease and
multiple sclerosis,10 and acute central nervous system injury
including ischemic and hemorrhagic stroke.11
It has been suggested that increased expression of HDAC
within the superficial dorsal horn is key to maintenance of
persistent pain.12 The pharmacological inhibition of class IIa
HDAC in the spinal cord has been shown to attenuate in-
flammatory complete-Freund’s-adjuvant-induced thermal
hyperalgesia in rats.13 Sodium valproate has been shown to
produce beneficial effects in different neuropathic pain
conditions, including those due to chemotherapeutic agents,
and its pain-attenuating effects have been at least partly
attributed to HDAC inhibition.14 Sodium butyrate is a
noncompetitive inhibitor of HDAC15 and it selectively inhibits
subtypes I and IIa.16 The present study was designed to
investigate the neuropathic-pain-attenuating potential of
sodium butyrate in chronic constriction injury (CCI)-induced
neuropathic pain in rats.
Materials and methods
Experimental animals
SpragueeDrawly rats of either sex weighing 200e250 g
(procured from Punjab University, Chandigarh, India) were
used in the present study. They were housed in the animal
house with free access to water and a standard laboratory
chow diet (Kisan Feeds, Mumbai, India). The rats were
exposed to normal cycle of 12 hours light and 12 hours dark.
The experimental protocol was duly approved by the
Institutional Animals Ethics Committee (IAEC) and care of
animals was carried out as per the guidelines of the Com-
mittee for the Purpose of Control and Supervision of Ex-
periments on Animals (CPCSEA), Ministry of Environment
and Forests, Government of India (Reg. No. e 107/1999/
CPCSEA).
Drugs and reagents
Sodium butyrate was obtained from SigmaeAldrich (St
Louis, MO, USA). Bovine serum albumin and FolineCicalteu
phenol reagent were obtained from S.D. Fine (Mumbai,
India). All the chemicals used in the present study were of
analytical grade. The tumor necrosis factor (TNF)-a assay
kit was procured from RayBiotech (Norcross, GA, USA).Induction of neuropathy by CCI
Peripheral neuropathy was induced by CCI as described
by Bennett and Xie with slight modification,17 using silk 4-
0 sutures instead of chromic gut sutures, because it has
been documented that the latter initiate inflammatory
reactions in the sciatic nerve.18 The rats were deeply
anesthetized with chloral hydrate (350 mg/kg, intraperi-
toneal). The hair on the lower back and thighs of the rats
was shaved, and the skin was sterilized with 0.5% chlor-
hexidine. The skin of the lateral surface of the left thigh
was incised and a cut made directly through the biceps
femoris muscle to expose the sciatic nerve. Once exposed,
the sciatic nerve was ligated with silk 4-0 thread at four
sites with a 1-mm gap. The ligatures were loosely tied
until a short flick of the ipsilateral hind limb was
observed. The muscle and skin were closed in two layers
with the use of thread, and topical antibiotics were
applied. All surgical procedures were carried out under
normal sterile conditions. As a result of the distinct
development of postural defects in the paws of CCI con-
trol animals, the behavioral studies were not blinded for
comparison between the normal controls, sham controls,
and CCI control groups. However, for all other groups the
behavioral tests were blinded.Behavioral examination
Paw cold allodynia (acetone drop test)
Cold allodynia was assessed by spraying 100 mL of acetone
onto the surface of the rat paw (placed over a wire mesh),
without touching the skin. The response of the rat to
acetone was noted for 20 seconds and was graded on a 4-
point scale as defined by Flatters and Bennett19 (0, no
response; 1, quick withdrawal, flick or stamp of the paw;
2, prolonged withdrawal or repeated flicking; and 3,
repeated flicking of the paw with licking of the paw).
Acetone was applied three times to the hind paw, with a
gap of 5 minutes between the acetone applications, and
the individual scores noted at 20-second intervals were
added to obtain a single score over a cumulative period of
1 minute. The minimum score was 0 and the maximum
possible score was 9.
Mechanical hyperalgesia (pin prick test)
Mechanical hyperalgesia was assessed by the pinprick test,
as described by Erichsen and Blackburn-Munro.20 The sur-
face of the injured hind paw was touched with the point of
a bent gauge needle (at 90 to the syringe) at intensity
sufficient to produce a reflex withdrawal response. The paw
withdrawal duration was recorded in seconds and the
normal quick reflex withdrawal response was given the
value of 0.5 seconds.
Paw heat hyperalgesia (hot plate test)
The thermal nociceptive threshold, as an index of thermal
hyperalgesia, was assessed by the Eddy’s hot plate, main-
tained at a temperature of 52.5  1.0C. The rat was
placed on the hot plate and withdrawal latency, with
respect to licking of the hind paw, was recorded in seconds.
The cut-off time of 15 seconds was maintained.21
Sodium butyrate in neuropathic pain 923Determination of mechanical allodynia by Von Frey hair
test
Mechanical allodynia (non-noxious mechanical stimuli) was
assessed as described by Chaplan et al.22 Calibrated nylon
filaments (Von Frey hairs), in terms of different bending
forces, were applied to the midplantar surface of left hind
paw. The filaments were applied 10 times, starting with the
softest and continuing in ascending order of stiffness. A
brisk withdrawal of the left hind limb was considered a
positive response. The criterion for the threshold value, in
grams, was equal to the filament evoking a withdrawal
threshold of the left hind paw five times out of 10 trials,
that is, a 50% response.
Biochemical estimations
Cytokine and protein assay
All the animals were sacrificed and the sciatic nerve
samples (7e8 mm long and taken along with the
shaft of the femur before sciatic trifurcation), were
isolated immediately for biochemical analysis. The sciatic
nerve was homogenized in phosphate-buffered saline, pH
7.4, and thereafter, the homogenates were processed
immediately for centrifugation at 1500g, at 4C for 10
minutes to obtain the supernatant for protein and TNF-a
estimation.
Estimation of protein content
The protein concentration in the sciatic nerve was esti-
mated according to the method of Lowry et al.,23 using
bovine serum albumin as a standard.
Estimation of TNF-a
TNF-a was estimated with a commercially available
enzyme-linked immunosorbent assay (ELISA, SUNOSTIK-
SPR-960 ELISA READER, Sunostik Medical Technology Co.,
Ltd, Jilin, Changchun, China). The concentration of TNF-a
was expressed in pg/mg of protein.Cold allod
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Figure 1 Effect of sodium butyrate on CCI-induced paw cold a
mean  standard error of the mean, n Z 6 rats per group. Two-w
F (1, 80) Z 1149.43, for days, p < 0.0001 and F (7, 80) Z 119.3
corresponding to same day. b p < 0.05 versus CCI corresponding to
corresponding to same day. CCI Z chronic constriction injury.Experimental protocol
Eight groups of six rats were used in the present study.
Group I: normal control. Rats were not subjected to any
treatment and were kept for 14 days. The behavioral tests
were performed on Day 0, Day 7, and Day 14. On Day 14,
the animals were sacrificed and the biochemical estima-
tions were carried out. Group II: sham control. Rats were
subjected to a surgical procedure to expose the left sciatic
nerve on Day 1, without any nerve ligation. The behavioral
tests were done on Day 1 (before surgery), Day 7, and Day
14, and the biochemical analysis was done as described for
Group I. Group III: CCI. Rats were subjected to a surgical
procedure to expose and ligate the left sciatic nerve on
Day 1 as described above. The behavioral tests and
biochemical analysis were done as described for Group II.
Groups IV, V, and VI: sodium butyrate in CCI. Sodium
butyrate [100 mg/kg, 200 mg/kg and 400 mg/kg, orally
(p.o.) by syringe feeder] was administered to rats sub-
jected to CCI, starting from Day 1 (30 minutes prior to
anesthesia for surgery) to Day 14. The behavioral tests and
the biochemical analysis were done as described for Group
II. Group VII: vehicle-treated rats with CCI. Saline (1 mL/
kg, p.o. by syringe feeder) was administered to rats sub-
jected to CCI, from Day 1 (30 minutes prior to anesthesia
for surgery) to Day 14. The behavioral tests and the
biochemical analysis were done as described for Group II.
Group VIII: sodium butyrate per se. Sodium butyrate
(400 mg/kg, p.o.) was administered to normal rats for 14
days. The behavioral tests and the biochemical analysis
were done as described for Group II.Statistical analysis
The results were expressed as the mean  standard error of
the mean. The data from the behavioral tests were
analyzed using two-way analysis of variance (ANOVA)ynia
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a a
a,b
a,b,c
llodynia assessed by acetone drop test. Values are given as
ay analysis of variance followed by Bonferonni’s post hoc test,
4 for treatment, p < 0.0001. a p < 0.05 versus sham control
same day. c p < 0.05 versus sodium butyrate 100 mg/kg in CCI
924 A. Kukkar et al.followed by Bonferonni’s post hoc test, using GraphPad
Prism version 5.0 (San Diego, California, USA). The data
from the biochemical tests were analyzed using one-way
ANOVA followed by Tukey’s multiple range test. A p
value < 0.05 was considered to be statistically significant.Results
Effect of sodium butyrate on hyperalgesia and
allodynia in CCI-induced neuropathic pain
CCI resulted in significant development of cold allodynia
(Fig. 1), mechanical allodynia (Fig. 2), mechanical hyper-
algesia (Fig. 3), and heat hyperalgesia (Fig. 4),as compared
to the sham group, assessed by acetone drop test, Von Frey
hair test, pin prick test, and hot plate test, respectively.
Administration of sodium butyrate (200 mg/kg and 400 mg/
kg, p.o.), for 14 days, significantly attenuated CCI-induced
hyperalgesia and allodynia on Day 7 and Day 14. However,
the pain symptoms were significantly higher on Day 14 as
compared to Day 7 (data not shown). Administration of
sodium butyrate (400 mg/kg, p.o.) did not modulate
behavioral function in normal rats. Administration of
vehicle did not alter CCI-induced hyperalgesia and
allodynia.Effect of sodium butyrate on TNF-a in CCI-induced
neuropathic pain
CCI significantly elevated TNF-a level in the sciatic nerve on
Day 14 as compared to that in sham control rats. Adminis-
tration of sodium butyrate (200 mg/kg and 400 mg/kg, p.o.)
significantly attenuated CCI-induced increase in TNF-a
level. Per se administration of sodium butyrate (400 mg/kg
p.o.) and the vehicle did not affect TNF-a in normal and
CCI-subjected rats, respectively (Fig. 5).Mechanical a
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Figure 2 Effect of sodium butyrate on CCI-induced mechanical
mean  standard error of the mean, n Z 6 rats per group. Two-w
F (1, 80) Z 137.07, for days, p < 0.0001 and F (7, 80) Z 12.17 fo
responding to same day. b p < 0.05 versus CCI corresponding to s
corresponding to same day. CCI Z chronic constriction injury.Discussion
TheCCImodel is themost commonly used animal neuropathic
pain model of nerve-damage-induced allodynia/hyper-
algesia.24,25 In this model, neuropathic pain is induced by
entrapping the sciatic nerve through four loose ligatures and
the model shares the pathophysiology of carpal tunnel syn-
drome in humans due to entrapment of the median nerve in
the narrowing tunnel. Furthermore, this model has also been
suggested to share the pathophysiology of complex regional
pain syndrome in humans.24,26 In the present study, CCI led to
a significant development of cold allodynia, mechanical
allodynia, mechanical hyperalgesia, and heat hyperalgesia
assessed on Day 7 and Day 14 after surgery. In our previous
studies, thepeakbehavioral alterationswere reportedonDay
14 day after the nerve injury in the CCI model.27
In the present investigation, administration of sodium
butyrate (200 mg/kg and 400 mg/kg, p.o.) for 14 days
significantly attenuated CCI-induced behavioral alterations
including paw cold allodynia, mechanical allodynia, and
mechanical and heat hyperalgesia. Several pharmacological
studies have shown the beneficial effects of sodium buty-
rate in different inflammatory conditions, such as a per-
manent ischemic model of stroke in rats, acute lung injury
during cecal ligation, and puncture-induced polymicrobial
sepsis.28,29 However, this is believed to be the first study
showing the beneficial effects of sodium butyrate in CCI-
induced neuropathic pain in rats. In the present study,
drug was administered for 14 days after the nerve injury,
therefore suggesting the therapeutic effect of sodium
butyrate in the CCI model. Sodium butyrate is a noncom-
petitive inhibitor of HDAC15 and it selectively inhibits mul-
tiple subtypes of class I and IIa.16 Previous studies have
suggested the key role of HDAC IIa in inflammatory pain
because complete-Freund’s-adjuvant-induced thermal
hyperalgesia is inhibited by HDAC IIa inhibition.13 Accord-
ingly, it may be tentatively proposed that sodium-butyrate-
mediated HDAC IIa inhibition is probably responsible for itsllodynia
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Figure 3 Effect of sodium butyrate on CCI-induced mechanical hyperalgesia assessed by pin prick test. Values are given as
mean  standard error of the mean, n Z 6 rats per group. Two-way analysis of variance followed by Bonferonni’s post hoc test,
F (1, 80) Z 1696.65, for days, p < 0.0001 and F (7, 80) Z 182.75 for treatment, p < 0.0001. a p < 0.05 versus sham control
corresponding to same day. b p < 0.05 versus CCI corresponding to same day. c p < 0.05 versus sodium butyrate 100 mg/kg in CCI
corresponding to same day. CCI Z chronic constriction injury.
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butyrate, being a nonselective inhibitor, may also have
produced the beneficial effect by inhibiting HDAC I. How-
ever, the present study data are not sufficient to differ-
entiate the role of HDAC I and IIa in the pain-attenuating
effect that in turn may be established with the use of more
selective pharmacological agents.
In the present study, CCI-induced neuropathic pain was
associatedwith an increase inTNF-a level in the sciatic nerve.
TNF-a appears early in the cytokine cascade, therefore, it is
considered to be a prototype proinflammatory mediator. The
role of TNF-a has been well documented in peripheral as well
central sensitization in neuropathic pain.30 The results of the
present study showing elevated levels of TNF-a in the sciaticHeat hypera
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Figure 4 Effect of sodium butyrate on CCI-induced heat hypera
mean  standard error of the mean, n Z 6 rats per group. Two-w
F (1, 80) Z 1256.39, for days, p < 0.0001 and F (7, 80) Z 118.9
corresponding to same day. b p < 0.05 versus CCI corresponding to
corresponding to same day. CCI Z chronic constriction injury.nerve, even on Day 14 in CCI-subjected rats, are consistent
with our previous studies27,31e33 and those from other labo-
ratories.34,35 By contrast, the studies based on neuropathic
pain in CCI-subjectedmice have demonstrated that the early
elevation of TNF-a in the sciatic nerve tends to normalize by
Day 336 or Day 7.37 It is difficult to explain this discrepancy
related to early, transient increased expression of TNF-a in a
mouse model and prolonged expression of TNF-a in a rat
model of CCI. At the most, the possible species difference
mayhave accounted for the different results in these studies.
Some studies have suggested the influence of species on TNF-
a production, and Foster and co-workers38 have demon-
strated that lipopolysaccharide-stimulated TNF-a production
is higher in rats than in mice.lgesia
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same day. c p < 0.05 versus sodium butyrate 100 mg/kg in CCI
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Figure 5 Effect of sodium butyrate on CCI-induced rise in TNF-a level in the sciatic nerve. Values are given as mean  standard
error of the mean, nZ 6 rats per group. One-way analysis of variance followed by Tukey’s multiple range test, F (7, 47)Z 24.54,
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926 A. Kukkar et al.The reduction in the levels of TNF-a may be attributed
to inhibition of HDAC because some studies have demon-
strated that HDAC inhibition reduces cytokine production;
particularly cytokines relevant to autoimmune/inflamma-
tory diseases.39 SAHA (suberoylanilide hydroxamic acid)
and ITF2357 (Givinostat) (HDAC inhibitors) have been shown
to reduce inflammation in animal models of diseases via
suppression of TNF-a, interleukin-1b, interferon-g, and
interleukin-6 production.40 The HDAC expression and ac-
tivity in synovial tissue of rheumatoid arthritis patients
correlates positively with the concentration of TNF-a,6 and
it has been shown that HDAC inhibitors suppress cytokine
production in rheumatoid synovial tissue explants.41,42 So-
dium butyrate also decreases proinflammatory cytokine
expression via inhibition of nuclear factor (NF)-kB activa-
tion and IkB-a (inhibitor of kappa -light-chain-enhancer of
activated B cells) degradation.43,44 Place and co-workers
have demonstrated that butyrate inhibits NF-kB activation
by HDAC-inhibition-induced suppression of proteasomal
activity and stabilizing IkB-a.45 These studies suggest the
relationship among HDAC, NF-kB, and TNF-a. It is possible
that the sodium-butyrate-mediated decrease in production
of cytokines, including TNF-a, is responsible for its noted
beneficial effects in the neuropathic pain in rats.
Recently, Zhang and co-workers46 have demonstrated that
during persistent inflammatory and neuropathic pain there is
histone hypoacetylation, which in turn causes suppression of
GABAergic (Gamma amino butyric acid) inhibitory activity,
and the effectiveness of HDAC inhibitors in restoring the
GABAergic activity in a spinal nerve ligation model. Earlier
studies have demonstrated that loss of GABA inhibitory ac-
tivity in the spinal neurons is associated with neuronal
hyperactivation, and restoration of GABA activity is effective
in relieving nerve-injury-induced pain.47,48 Furthermore,
some studies have shown that increased TNF-a levels in
neuronal cultures and hippocampal slices decrease GABA
inhibitory activity.49,50 Based on these results, it may behypothesized that the sodium-butyrate-mediated decrease in
TNF-a levels and restoration of GABAergic activity are
responsible for relieving neuropathic pain in CCI models.
The major limitation of the present work was the lack of
direct evidence regarding the involvement of HDAC inhibi-
tion in the sodium-butyrate-mediated pain attenuation in
CCI-induced neuropathic pain. Therefore, future studies
may be directed to study the upregulation of HDAC in
neuropathic pain and correlate its upregulation with the
generation of proinflammatory cytokines.
In conclusion, sodium butyrate attenuates neuropathic
pain manifestations in a CCI model, which may possibly be
attributed to its ability to decrease the release of proin-
flammatory mediators during the nerve injury condition.Acknowledgments
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